Serplulimab: First Approval

Serplulimab (汉斯状 ® ) is an intravenously administered anti-PD-1 antibody being developed by Shanghai Henlius Biotech, Inc. for the treatment of solid tumours. Anti-PD-1 immunotherapies, such as serplulimab, can stimulate immune responses by relieving PD-1-related immunosuppression. Serplulimab recei...

Full description

Saved in:
Bibliographic Details
Published in:Drugs (New York, N.Y.) N.Y.), 2022-07, Vol.82 (10), p.1137-1141
Main Author: Lee, Arnold
Format: Article
Language:English
Subjects:
AdisInsight Report
Anemia
Antibodies
Binding sites
Biological products
Blood
Cancer therapies
Cervical cancer
Colorectal cancer
Gastric cancer
Immune response
Immunosuppression
Immunotherapy
Internal Medicine
Intestinal obstruction
Kidney diseases
Lung cancer
Medicine
Medicine & Public Health
Metastases
Metastasis
Microsatellite instability
Microsatellites
Patients
PD-1 protein
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Solid tumors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Serplulimab (汉斯状 ® ) is an intravenously administered anti-PD-1 antibody being developed by Shanghai Henlius Biotech, Inc. for the treatment of solid tumours. Anti-PD-1 immunotherapies, such as serplulimab, can stimulate immune responses by relieving PD-1-related immunosuppression. Serplulimab received its first approval on 25 Mar 2022 in China for the treatment of adult patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) solid tumours that have failed to respond to previous standard treatments. This article summarizes the milestones in the development of serplulimab leading to this first approval in the treatment of MSI-H solid tumours in adults.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-022-01740-0